GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nxera Pharma Co Ltd (OTCPK:SOLTF) » Definitions » Cyclically Adjusted FCF per Share

Nxera Pharma Co (Nxera Pharma Co) Cyclically Adjusted FCF per Share : $0.23 (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Nxera Pharma Co Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Nxera Pharma Co's adjusted free cash flow per share for the three months ended in Mar. 2024 was $-0.168. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $0.23 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Nxera Pharma Co's average Cyclically Adjusted FCF Growth Rate was -18.60% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 7.60% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 10.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Nxera Pharma Co was 26.50% per year. The lowest was 7.60% per year. And the median was 8.10% per year.

As of today (2024-05-22), Nxera Pharma Co's current stock price is $8.92. Nxera Pharma Co's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was $0.23. Nxera Pharma Co's Cyclically Adjusted Price-to-FCF of today is 38.78.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Nxera Pharma Co was 145.53. The lowest was 29.94. And the median was 60.21.


Nxera Pharma Co Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Nxera Pharma Co's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nxera Pharma Co Cyclically Adjusted FCF per Share Chart

Nxera Pharma Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.21 0.26 0.33 0.25 0.26

Nxera Pharma Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.33 0.30 0.28 0.26 0.23

Competitive Comparison of Nxera Pharma Co's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Nxera Pharma Co's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nxera Pharma Co's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nxera Pharma Co's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Nxera Pharma Co's Cyclically Adjusted Price-to-FCF falls into.



Nxera Pharma Co Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Nxera Pharma Co's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.168/107.2000*107.2000
=-0.168

Current CPI (Mar. 2024) = 107.2000.

Nxera Pharma Co Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 0.057 98.000 0.062
201409 -0.014 98.500 -0.015
201412 0.015 97.900 0.016
201503 -0.049 97.900 -0.054
201506 0.166 98.400 0.181
201509 0.066 98.500 0.072
201512 0.436 98.100 0.476
201603 -0.098 97.900 -0.107
201606 1.917 98.100 2.095
201609 -0.181 98.000 -0.198
201612 -0.058 98.400 -0.063
201703 0.076 98.100 0.083
201706 -0.038 98.500 -0.041
201709 -0.001 98.800 -0.001
201712 -0.037 99.400 -0.040
201803 -0.291 99.200 -0.314
201806 -0.274 99.200 -0.296
201809 -0.309 99.900 -0.332
201812 -0.142 99.700 -0.153
201903 0.027 99.700 0.029
201906 -0.045 99.800 -0.048
201909 0.492 100.100 0.527
201912 -0.096 100.500 -0.102
202003 0.164 100.300 0.175
202006 -0.050 99.900 -0.054
202009 0.134 99.900 0.144
202012 0.308 99.300 0.333
202103 -0.108 99.900 -0.116
202106 -0.066 99.500 -0.071
202109 -0.160 100.100 -0.171
202112 0.996 100.100 1.067
202203 -0.174 101.100 -0.184
202206 -0.154 101.800 -0.162
202209 0.677 103.100 0.704
202212 0.435 104.100 0.448
202303 -0.118 104.400 -0.121
202306 -0.164 105.200 -0.167
202309 -0.145 106.200 -0.146
202312 -0.097 106.800 -0.097
202403 -0.168 107.200 -0.168

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Nxera Pharma Co  (OTCPK:SOLTF) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Nxera Pharma Co's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=8.92/0.23
=38.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Nxera Pharma Co was 145.53. The lowest was 29.94. And the median was 60.21.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Nxera Pharma Co Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Nxera Pharma Co's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Nxera Pharma Co (Nxera Pharma Co) Business Description

Industry
Traded in Other Exchanges
Address
2-1 Kojimachi, Chiyoda-ku, PMO Hanzomon 11th Floor, Tokyo, JPN, 102-0083
Sosei Group Corp is an international biopharmaceutical company that develops treatments for a wide range of illnesses. The company utilizes its peptide platform technologies and nanotechnology to develop its product pipeline. Sosei actively seeks partnerships to aid its product development. The company's strategy for commercializing its therapies include utilizing its subsidiaries' drug discovery technologies, supplying technology to other companies, developing products in-house, and product licensing.

Nxera Pharma Co (Nxera Pharma Co) Headlines

From GuruFocus